Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

OBJECTIVE: In patients with moderate to severe albuminuric kidney disease, sodium–glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post hoc analyses assess the effects of dapagliflozin on kidney function decline in patients with type 2 diabetes (T2D), focusing...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosenzon, Ofri, Raz, Itamar, Wiviott, Stephen D., Schechter, Meir, Goodrich, Erica L., Yanuv, Ilan, Rozenberg, Aliza, Murphy, Sabina A., Zelniker, Thomas A., Langkilde, Anna Maria, Gause-Nilsson, Ingrid A.M., Fredriksson, Martin, Johansson, Peter A., Wilding, John P.H., McGuire, Darren K., Bhatt, Deepak L., Leiter, Lawrence A., Cahn, Avivit, Dwyer, Jamie P., Heerspink, Hiddo J.L., Sabatine, Marc S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862307/
https://www.ncbi.nlm.nih.gov/pubmed/35997319
http://dx.doi.org/10.2337/dc22-0382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862307/
https://www.ncbi.nlm.nih.gov/pubmed/35997319
http://dx.doi.org/10.2337/dc22-0382

Ejemplares similares